공지 : 도쿄증권거래소 JASDAQ 스탠다드 시장 신규 상장 관련 안내

Global Information
회사소개 | 문의 | 비교리스트

거대세포바이러스(HHV-5) 감염증 : 파이프라인 리뷰

Cytomegalovirus (HHV-5) Infections (Infectious Disease) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 09월 상품 코드 229755
페이지 정보 영문 200 Pages
가격
US $ 2,000 ₩ 2,395,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 4,790,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,185,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


거대세포바이러스(HHV-5) 감염증 : 파이프라인 리뷰 Cytomegalovirus (HHV-5) Infections (Infectious Disease) - Drugs in Development, 2021
발행일 : 2021년 09월 페이지 정보 : 영문 200 Pages

본 상품은 영문 자료로 한글과 영문목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

거대세포바이러스(CMV)는 헤르페스 바이러스의 일종으로, 전염성 감염증을 일으킵니다. CMV는 타액이나 소변을 통해 전염됩니다. 발열, 폐렴, 체중 감소, 난청, 신경장애, 발달장애 등의 증상이 나타납니다. 질병 소인으로서 감염된 표면 및 생물과의 직접 접촉 외에도 면역력 저하, 선천성 요인 등을 들 수 있습니다. 진단은 혈액검사나 소변 검사로 가능합니다. 증상은 약물(항바이러스 약물 등)로 억제되며, 생활습관 개선을 통해 예방할 수 있습니다.

거대세포바이러스(HHV-5) 감염증 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등의 정보를 전해드립니다.

목차

서론

거대세포바이러스(HHV-5) 감염증 개요

치료제 개발

치료제 평가

치료제 개발 참여 기업

약제 개요

휴지 상태의 프로젝트

개발이 중지된 제품

제품 개발 마일스톤

부록

도표

LSH 17.07.24

List of Tables

List of Tables

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Companies, 2021 (Contd..1)
  • Number of Products under Development by Companies, 2021 (Contd..2)
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products under Development by Universities/Institutes, 2021 (Contd..1)
  • Products under Development by Companies, 2021
  • Products under Development by Companies, 2021 (Contd..1)
  • Products under Development by Companies, 2021 (Contd..2)
  • Products under Development by Companies, 2021 (Contd..3)
  • Products under Development by Universities/Institutes, 2021
  • Products under Development by Universities/Institutes, 2021 (Contd..1)
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Target, 2021 (Contd..1)
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Abhelix LLC, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AlloVir Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by AlphaVax Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Artemis Therapeutics Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Biotest AG, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Chengdu Rongsheng Pharmaceutical Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Biologic Products Holdings Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by China Immunotech Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Citranvi Biosciences LLC, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Danuvius BioSciences, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Evrys Bio, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by GlaxoSmithKline Plc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Helocyte Biosciences Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Hookipa Pharma Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Huinuo Biomedical Technology Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by iCELL Biotechnology Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Karyopharm Therapeutics Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Memo Therapeutics AG, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Merck & Co Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Microbiotix Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Moderna Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Nobelpharma Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Okogen Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Orgenesis Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Phoenix Biotechnology Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Prosit Sole Biotechnology (Beijing) Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Provention Bio Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Savoy Pharmaceuticals Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Shanxi Kangbao Biological Product Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by SL VaxiGen Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by SpyBiotech Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Stadius Biopharma LLC, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Synklino ApS, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Takeda Pharmaceutical Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Themis Bioscience GmbH, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Trellis Bioscience Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by VBI Vaccines Inc, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Vichem Chemie Research Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Viramatix Sdn Bhd, 2021
  • Cytomegalovirus (HHV-5) Infections - Pipeline by Zhuhai Trinomab Biotechnology Co Ltd, 2021
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..1)
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..2)
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..3)
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects, 2021 (Contd..4)
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Cytomegalovirus (HHV-5) Infections, 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Top 10 Molecule Types, 2021
  • Number of Products by Stage and Top 10 Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Cytomegalovirus Infections - Drugs In Development, 2021, provides an overview of the Cytomegalovirus Infections (Infectious Disease) pipeline landscape.Cytomegalovirus (CMV) is a contagious infection of the caused by the member of the herpes virus family. CMV is spread through saliva or urine. Symptoms include fever, pneumonia, weight loss, hearing, neurological and developmental problems. The predisposing factors are exposure direct contact with infected surface or organism, weakened immune system and congenital factors. It may be diagnosed by blood or urine tests. The condition may be controlled by the use of medication such as anti-viral and may be prevented by lifestyle modification.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Cytomegalovirus Infections - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Cytomegalovirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Cytomegalovirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Cytomegalovirus (HHV-5) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 1, 2, 9, 8, 21, 9 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Phase I, Phase 0, Preclinical and Discovery stages comprises 2, 9, 11, 2, 6 and 3 molecules, respectively.

Cytomegalovirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Cytomegalovirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Cytomegalovirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Cytomegalovirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Cytomegalovirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Cytomegalovirus Infections (Infectious Disease)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Cytomegalovirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Cytomegalovirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

  • Introduction
  • Cytomegalovirus (HHV-5) Infections - Overview
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Development
  • Cytomegalovirus (HHV-5) Infections - Therapeutics Assessment
  • Cytomegalovirus (HHV-5) Infections - Companies Involved in Therapeutics Development
  • Cytomegalovirus (HHV-5) Infections - Drug Profiles
  • Cytomegalovirus (HHV-5) Infections - Dormant Projects
  • Cytomegalovirus (HHV-5) Infections - Discontinued Products
  • Cytomegalovirus (HHV-5) Infections - Product Development Milestones
  • Appendix
Back to Top
전화 문의
F A Q